In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Benefits from vitamin D supplementation in kidney disease vary; routine testing is not recommended in otherwise healthy ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

chronic kidney disease and those who are overweight or obese. It is also approved for similar trials in the U.S. The deal comes as Novo Nordisk works to expand its lineup of advanced weight-loss ...

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by the American Heart Association, a global force changing the future ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Eli Lilly & Co. has disclosed new calcium/calmodulin-dependent 3’,5’-cyclic nucleotide phosphodiesterase 1 (PDE1) inhibitors reported to be useful for the treatment of chronic kidney disease, ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...